Introduction
Patulous Eustachian tube (PET) is a pathologic state characterized by symptoms of aural fullness, autophony, and the hearing of physiologic breathing sounds, which was first described in the late 1800s by Schwartze [
1] and Jago [
2]. The Eustachian tube (ET) links the middle ear to the nasopharynx, which is usually closed at rest and transiently opens during normal swallowing. However, abnormal persistent opening of the valve at rest leads to symptoms of PET [
3].
Most cases subside spontaneously, but there are some intractable cases that require surgical procedures. Surgical treatments can be classified into three categories: 1) narrowing of the lumen of the ET by injecting a bulky agent, 2) surgical ligation of the ET orifice, and 3) plugging of the lumen with various materials [
4].
Surgical treatments are ultimately undertaken to obstruct the ET lumen. Trials to obstruct the ET lumen have been conducted by various means, such an indwelling catheter [
5], a silicone plug [
6], and cartilage block [
7], in addition to injecting small pieces of cartilage [
8]. We modified the tragal cartilage plugging method, which was first reported by Kobayashi [
7]. Our method can eliminate the risk of foreign body, while being considered more physiologic as it can reduce damage to Eustachian valve. Here, we evaluated the feasibility of modified tragal cartilage chip insertion technique via transcanal approach for treatment of PET.
Discussion
The optimal treatment for PET has not been established clearly, and depends on the severity of the symptoms [
6]. Conservative methods are usually recommended, such as sufficient hydration, weight gain, saline nasal irrigation, and reassurance [
4]. Some medications, including anxiolytics, Chinese herbal medicines, sympathomimetic agents [
6], nasal steroid sprays, estrogen nasal solution, and topical irritants to induce mucosal edema [
4], are helpful.
However, surgical methods are required in some intractable and persistent cases. Physiologically, closure of the ET is maintained by the mucosal valve of the cartilaginous portion, which is approximately 5 mm in length and is located about 10 mm distal to the tube from the torus tubarius [
3]. Different surgical trials have been conducted aiming to narrow the lumen of ET, with varying success rates (
Table 5) [
5,
10-
17].
Previously, Kobayashi [
7] tried to treat PET using the transtympanic cartilage insertion method. However, they changed the plugging material to tailored silicon tube. The average length of ET from middle ear orifice to nasopharyngeal orifice was about 35 mm, and its isthmus was about 12 mm distance from middle ear orifice. Therefore, they thought it was difficult to completely obstruct or probe the valve portion of ET. Thus, they designed a 22- to 25-mm-long silicon tube and reported good results [
6]. After modifying the shape of this silicon tube, they recently reported that success rate of these old and new type silicon tubes for PET was 83.0%, based on evaluation of 252 ears from 191 patients [
18]. Despite these favorable results, there are still some limitations in this silicon tube insertion technique: first, it may cause a foreign body reaction in the tissue; second, normal bony portion of ET and the narrow isthmus structure could be injured when the silicon tube passes through them; and lastly, otitis media with effusion may occur if ET is obstructed completely with a silicon tube.
If we can use cartilage chip more efficiently and firmly, we can achieve more favorable results while reducing the risk of foreign body reaction, maintaining physiologic function such as middle ear gas exchange and clearing of middle ear secretions, and preventing the possibility of middle ear effusion or otitis media.
Our modified transtympanic cartilage insertion technique is different from the original technique used by Kobayashi [
7]. We used longer cartilage chip which can reach ET isthmus, even though it cannot pass through the isthmus. We also used two more cartilage chips and perichondrium to reinforce the first cartilage chip, and to reduce the recurrence of symptoms resulting from tissue absorption.
Although our technique neither crosses the isthmus nor completely closes the valve, it can sufficiently obstruct the isthmus. More than 92% of examined ears showed complete symptom relief immediately, and this was the evidence of sufficient obstruction. Cartilage can reach and obstruct the isthmus (
Fig. 1). During more than 12 months of follow-up, two-thirds of the patients maintained their improvement, and this was similar to the results from other previous reports, some of which used silicone tubes (
Table 5). We performed revision surgery, of which the result was not included in this study, in one patient who had no improvement in symptoms after eight months since first surgery, and found that the previously inserted cartilage was not absorbed. In this respect, it is supposed that the absorption is slight and the effect of insertion persists for a long time.
This type of insertion has some benefits compared with silicon tube insertion that crosses the isthmus. First, this procedure does not involve complete passage through the valve, so it can reduce the risk of injury to structures surrounding the valve and possible complications. Despite the lack of complete passage through the valve, the symptoms were improved significantly. Second, autologous tragal cartilage is used to reduce the risk of a foreign body reaction compared with the method that uses a foreign silicon tube. Third, the risk of otitis media resulting from complete closure in other previously reported methods is reduced. Fourth, our technique is easier than other previously reported methods. It is not necessary for the insertion to be deep enough to pass completely through the valve. Also, tympanomeatal flap elevation and myringoplasty need not be performed to facilitate the handling of inserted material. Finally, the use of autologous cartilage requires no additional approval from the Food and Drug Administration (FDA), as well as no additional cost for buying the material.
At the last follow-up visit in some patients, postoperative autophony symptom scores were slightly higher than those at the immediate follow-up visit. These patients with recurred symptoms had surgery in early period. During early period, we did not obstruct the isthmus completely to reduce the risk of otitis media, and we believe this gap could have induced absorption of inserted cartilage and recurrence of symptoms. However, we later inserted cartilage to completely obstruct the isthmus, considering slight absorption of cartilage with passage of time.
Nevertheless, voice echoing, which is associated with autophony, was improved significantly at the immediate and final follow-up visits. Based on these results, we determined that some symptoms that are related to autophony seem to re-appear, although the severity of the symptoms seems to be improved.
In our method, once myringotomy and ET orifice probing is performed, only the trimmed cartilage needs to be inserted into the orifice, which is then obstructed with perichondrium. Due to the ease of handling, the estimated time of surgery is short—approximately 30 minutes—and the surgery can be completed under local anesthesia.
In conclusion, transtympanic cartilage chip insertion into the ET via the transcanal anterior superior myringotomy technique represents a safe and accessible surgical option for the treatment of PET and provides a reliable and satisfactory outcome for PET patients.